8-K: GRI Bio Reports Full Year 2024 Financial Results and Provides Clinical Update on IPF Treatment

GRI Bio announced its full year 2024 financial results and reiterated its expectation for clinical data readouts in 2025 for its Phase 2a study of GRI-0621 in Idiopathic Pulmonary Fibrosis (IPF).

Summary

• GRI Bio reported a net loss of $8.2 million for the year ended December 31, 2024.
• Research and development expenses increased by $0.6 million to $3.8 million in 2024, primarily due to the development program for GRI-0621.
• General and administrative expenses decreased by $3.7 million to $4.5 million, mainly due to reduced fees related to the merger with Vallon Pharmaceuticals in 2023.
• As of December 31, 2024, GRI Bio had approximately $5.0 million in cash and cash equivalents.
• The company expects its cash to fund operations into Q2 2025, including the interim data readout from the GRI-0621 Phase 2a study.
• Interim data from the Phase 2a biomarker study of GRI-0621 is expected in Q2 2025, with topline data expected in Q3 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there's progress in clinical development and a decrease in some expenses, the limited cash runway and the need for potential future capital raises temper the positive aspects.

Positives

• GRI Bio is making significant progress on the development of GRI-0621 for IPF.
• Positive preclinical data supports the potential of GRI-0621 to reduce inflammatory and fibrotic drivers in IPF.
• The European patent grant strengthens the company's intellectual property position.
• The company anticipates interim and topline data readouts from the Phase 2a study of GRI-0621 in 2025.
• General and administrative expenses decreased significantly due to reduced merger-related fees.

Negatives

• GRI Bio reported a net loss of $8.2 million for the year ended December 31, 2024.
• The company's cash runway is expected to fund operations only into Q2 2025, raising concerns about future funding needs.

Risks

• The company's cash and cash equivalents may not be sufficient to fund operations beyond Q2 2025.
• The company may need to raise additional funds, which may not be available on acceptable terms or at all.
• Clinical trial results may not be indicative of results of later studies or clinical trials.
• The company faces risks related to obtaining and maintaining regulatory clearance or approval for its products.
• The company faces risks related to protecting and enforcing its intellectual property portfolio.

Future Outlook

GRI Bio expects to report interim data from its Phase 2a biomarker study of GRI-0621 in Q2 2025 and topline results in Q3 2025. The company believes its existing cash will fund operations into Q2 2025.

Management Comments

• Marc Hertz, PhD, Chief Executive Officer of GRI Bio, commented that the company continues to make strides towards its anticipated interim data readout and topline data readout which remains on track for the second and third quarter of 2025, respectively.
• Marc Hertz also stated that the company remains confident that the data observed to date and the additional data readouts anticipated this year, will position them to build momentum and drive value for shareholders in the near and long term.

Industry Context

GRI Bio is focused on developing therapies for inflammatory, fibrotic, and autoimmune diseases, specifically targeting NKT cells. The company's lead program, GRI-0621, is being developed for IPF, a disease with limited treatment options and significant unmet need. The company is leveraging the 505(b)(2) regulatory pathway, which could expedite the approval process.

Comparison to Industry Standards

• GRI Bio is developing GRI-0621 for IPF, a market currently dominated by drugs like Ofev (nintedanib) from Boehringer Ingelheim and Esbriet (pirfenidone) from Roche/Genentech.
• These existing treatments have limitations in terms of side effects and impact on overall survival, creating an opportunity for new therapies like GRI-0621.
• GRI Bio's approach of targeting iNKT cells represents a novel mechanism of action compared to existing IPF treatments.
• The company's use of the 505(b)(2) regulatory pathway is a common strategy for companies developing drugs with existing data, potentially reducing development time and costs.

Stakeholder Impact

• Shareholders: The company's progress in clinical development and potential for future value creation could benefit shareholders.
• Employees: Continued funding and successful clinical trials could provide job security and growth opportunities for employees.
• Patients: Successful development of GRI-0621 could provide a new treatment option for patients with IPF.
• Investors: The company's need for additional funding could impact potential investors.

Next Steps

• Report interim data from Phase 2a biomarker study of GRI-0621 in Q2 2025.
• Report topline results from Phase 2a biomarker study of GRI-0621 in Q3 2025.
• Continue development of GRI-0621 for the treatment of IPF.
• Potentially seek additional funding to support operations beyond Q2 2025.

Key Dates